Siyu MedTech Announces '2023 Global Innovative Medical Device Awards' and Unveils Top 20 Breakthrough Devices

Zimmer Biomet: Persona IQ® Smart Knee Replacement Implant

Persona IQ® Smart Knee Replacement Prosthesis is developed by Zimmer Biomet in collaboration with Canary Medical.New product, FDA granted the product marketing authorization for total knee arthroplasty in August 2021.

Persona IQ Aims to Provide Intelligent Postoperative Metrics for Patients. Canary Company Designed a Hollow Stem for the Implant, Which Contains a Battery, Accelerometer, Gyroscope, and Pedometer to Track Activity Data. Through the Sensor Designed by Canary Company, Persona IQ Can Measure the Patient’s Range of Motion, Step Count, Stride Length, and Walking Distance from Inside the Body. It Can Also Detect Issues with the Implant and Help Patients Adjust Their Gait.

It is reported that Persona IQ® isThe world's first and only smart knee implant to receive FDA approval for total knee replacement surgery.

For details, see the link:Latest! This Hospital Introduces Smart Knee Joint Technology

Siemens Healthineers: NAEOTOM Alpha Photon Counting CT

The product consists of a gantry, high-voltage generator, X-ray tube and X-ray tube assembly, collimator, photon-counting detector, power distribution unit, patient table, laser, console, image processing software, control host, and reconstruction workstation. It is used for routine CT examinations and supports coronary CT angiography and spectral imaging.

The product adoptsChina's First Innovative Technology of Photon Counting Detector, capable of calculating the number of incident X-ray photons and measuring the energy levels of photons. Compared with CT using traditional energy-integrating detectors, this product has higher spatial resolution, can directly obtain spectral images, and can further meet the needs of clinical imaging diagnosis.

For details, see the link:Approved by NMPA! The World's First Photon-Counting CT

TactiFlex features a flexible design for the treatment of arrhythmias. With directional infusion and tip temperature monitoring technology, it provides operators with a safe and efficient ablation experience, helping to reduce cardiac ablation procedure time.

TactiFlex Ablation Catheter with Scale-like Etched Tip, Magnetic and Electric Positioning, Pressure Monitoring, and Optical Pressure Sensing Design. It bends upon contact with the heart wall to guide the flow of irrigation fluid to the target tissue.

The product was approved by the FDA in May 2023.It is the world's first and only ablation catheter with a flexible electrode tip that measures contact pressure.

Reach Neuro, established in 2021 as a spin-off company from the University of Pittsburgh and Carnegie Mellon University, is currently collaborating with the University of Pittsburgh Medical Center (UPMC) to test Avantis in an NIH-funded clinical trial.

The company develops implantable neuromodulation systems aimed at restoring upper limb motor function in patients with chronic stroke and other neurological disorders. The company aims to bring advanced neurotechnology from the lab to patients. Its mission is to change people's perceptions of physical rehabilitation and end the concept of permanent disability.

SpectraWAVE, founded in 2017 and located in Massachusetts, USA, is a medical imaging company dedicated to improving the treatment and prognosis of patients with coronary artery disease (CAD). The SpectraWAVE medical imaging platform represents the most advanced integration of proven imaging technologies, designed to assist interventional cardiologists in understanding patients and optimizing interventions.

The NMPA official website shows that the product is composed of implanted components, external components, and surgical accessories. It is used in conjunction with specific artificial blood vessels to provide mechanical support for blood circulation in patients with advanced refractory left heart failure, serving as a transitional treatment before heart transplantation or for restoring heart function.

This product is a third-generation non-contact magnetic levitation centrifugal pump. Its core technology mainly involves disc motor technology, which uses position sensors to detect and control the rotor's speed and suspension height. The product's motor employs only one set of stator coils to simultaneously control the rotor’s rotation and suspension, making the structure simpler, weight lighter, size smaller, and power consumption lower. In clinical applications, the surgical incision is smaller, patient recovery is faster, the applicable population is broader, and it can reduce the risk of thrombosis caused by blood pump heat.

For details, see the link.Connected to:Latest! Another Artificial Heart Approved by NMPA!

Shenzhen Core Medical Technology Co., Ltd. was established in August 2016, with its headquarters located in Shenzhen, China.Is a national high-tech enterprise dedicated to the research, development, and production of innovative high-end medical device products such as mechanical circulatory assist devices (commonly known as "artificial hearts"), and is currently the only company in the world.Companies simultaneously developing implantable and interventional artificial heart products。

As shown on the NMPA official website，The product, which consists of a magnet, examination bed, spectrometer, gradient power amplifier, RF power amplifier, xenon RF power amplifier, power distribution system, physiological signal gating unit, and more, has independent intellectual property rights. Based on a conventional magnetic resonance imaging system, this product adds the function of xenon nucleus imaging, enabling gas to be distributed in the lungs in a non-invasive and radiation-free manner. It is China's first magnetic resonance imaging system that can be used for pulmonary gas imaging.

For details, see the link.To be continued:Latest! Innovative MRI System Approved for Marketing!

Zhongke Polarization, established in 2018, is a high-tech enterprise integrating the research and development, production, and sales of medical devices. It was jointly founded by the Innovation Academy for Precision Measurement Science and Technology of the Chinese Academy of Sciences (formerly the Wuhan Institute of Physics and Mathematics of the Chinese Academy of Sciences), Hengdian Group ("Top 500 Chinese Private Enterprises"), and United Imaging Healthcare ("a leading manufacturer of high-end imaging equipment in China").

NMPA Official WebsiteIt shows that the ValveClamp® Mitral Valve Clip System consists of a mitral valve clip, delivery system, and transvalvular device. Among these, the delivery system comprises a delivery tool, pusher, loader, catheter sheath, and dilator. The use of this product eliminates the need for cardiac arrest and extracorporeal circulation during surgery, with a small incision, short surgical pathway, and direct positioning; furthermore, the procedure is guided purely by ultrasound, preventing both doctors and patients from being affected by X-rays. The mitral valve clip offers a larger capture range, which facilitates operation; it adopts a closed-loop design, making it less likely for the clip arms to separate.Open, ensure a secure closure.

This product adopts the transapical surgical approach and is suitable for patients with degenerative mitral regurgitation (MR≥3+) who are assessed by a professional cardiac team as having a high surgical risk and whose mitral valve anatomy is appropriate. The underlying conditions of these patients should not affect the clinical benefits brought about by reducing mitral regurgitation. The market launch of this product will provide more options for clinical treatment.

According to public information, this product is the first domestically produced mitral regurgitation interventional device approved for marketing in China.

For details, see the link.To:First Made-in-China! Mitral Regurgitation Intervention Device Launched

Yongxin Medical was established in June 2011 as a high-tech industrialization platform co-founded by Mr. Cao Guangbiao, a patriotic Hong Kong industrialist dedicated to serving the country through industry, and Tsinghua University. The company focuses on the research, development, production, and sales of advanced medical imaging equipment and sophisticated medical processing software with full independent intellectual property rights, as well as the provision of related services.

Wuhan Chujingling Medical Technology Co., Ltd. is a high-tech innovation enterprise dedicated to the development of artificial intelligence software products in multiple clinical medical fields such as gastroenterology, respiratory medicine, ophthalmology, and pathology. The company's founders and R&D team possess cutting-edge artificial intelligence deep learning technology and specialize in the research, development, and promotion of AI products in the medical field.

NMPA Official WebsiteTINGSN Sonic Eyes 10 consists of a catheter body, an operating handle, and a connector. When used with the company's portable color ultrasound diagnostic instrument, it is suitable for medical institutions to perform ultrasound imaging of the heart, major cardiac vessels, and intracardiac anatomical structures.

This product performs two-dimensional imaging and three-dimensional modeling of the cardiac region using high-frequency ultrasound, enabling accurate, rapid, and efficient ultrasound-guided surgery. It provides real-time, precise anatomical images while monitoring hemodynamic changes, displaying cardiac tissue characteristics and fine structures with clarity. It allows for real-time monitoring to promptly identify surgery-related complications, ensuring maximum surgical safety. The launch of this product is expected to reduce clinical treatment costs, benefiting more patients.

It is reported that this product is the first domestically developed and approved high-end intracardiac ultrasound diagnostic catheter in China.

TingSheng Technology was founded in 2019, with its headquarters located in Nanjing, Jiangsu, and research and development centers established in both China and the United States.CompanyFocusing on the R&D of globally leading cardiac electrophysiology interventional surgical instruments, breaking the foreign monopoly in the Chinese market, and surpassing domestic competitors with advanced technology. Committed to enabling more patients with heart disease in non-developed areas to receive effective treatment, becoming an influential medical device.Made in China brand.

The DragonFly™ Transcatheter Mitral Valve Clip System, the first Chinese-produced transcatheter mitral valve edge-to-edge repair device via femoral vein, received support from the "14th Five-Year Plan" National Key Research and Development Program in 2022.

NMPA Official WebsiteIndicates,The product consists of two components: a guiding sheath and a mitral clip system. The mitral clip system includes a mitral clip and a delivery system. The elastic central occlusion mesh structure of the mitral clip can enhance sealing, reduce central residual regurgitation, and decrease leaflet clamping force. Additionally, the mitral clip is designed with functions such as individual leaflet capture and repositioning, which can improve operational precision and reduce the risk of clip detachment and leaflet perforation.

This product is suitable for patients with degenerative mitral regurgitation (MR≥3+) who are assessed by the heart team as having a high surgical risk and whose mitral valve anatomy is appropriate. The availability of this product will provide more options for clinical treatment.

Hangzhou Dejin Medical Technology Co., Ltd. was established in 2015, with its headquarters located in Binjiang District, Hangzhou National High-tech Development Zone, and an innovation R&D center in Shenzhen. The company focuses on interventional treatment products and technologies for mitral and tricuspid valve diseases. It has been successively recognized as a national and Zhejiang provincial technology-based small and medium-sized enterprise, Hangzhou High-tech Research and Development Center, and Hangzhou Engineering Research Center. In 2022, it led the undertaking of the national "14th Five-Year Plan" key R&D program and participated in multiple national and provincial key R&D programs. In 2020, it was named a Chinese unicorn company. Globally, it has applied for more than 500 patents, of which over 150 have been granted.

The venous stent system consists of a self-expanding nitinol stent and a delivery system. The self-expanding stent is braided from nitinol wires and features flexibility, kink resistance, and fatigue resistance. This product has a unique release self-compensation structure to ensure stable and precise stent deployment during surgery. It also has a retrievable function, allowing 90% of the stent length to be retracted back into the delivery system and redeployed once if the venous stent has not been fully pushed out of the delivery system, resolving any abnormal issues during deployment and enhancing product safety.

This product is intended for use in the iliac and femoral veins to treat non-thrombotic iliac vein compression syndrome and post-thrombotic syndrome. The market launch of this product will provide more options for clinical treatment.

For details, see the link.To:Latest! Another Innovative Medical Device Approved for Marketing!

Suzhou Inlaid Medical Device Co., Ltd. was founded in 2013, as a company specializing in peripheral vascular devices and high-endDeep in the field of consumablesExperts with extensive R&D experienceGong Xiaoyan founded a national new technology enterprise, which is professionally dedicated to the research, development, and manufacturing of implantable medical device products and interventional high-end consumables.Currently, the company has 6 overseas-returning doctors and 9 master's degree holders, with over 50 employees in total.The company has applied for more than 70 patents, several of which have entered Europe and the United States.